ClinicalTrials.gg
RecruitingNCT07006662(LaPBrecon)Updated Sep 9, 2026

Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction

An observational study in Breast Cancer Female, sponsored by University Hospitals of North Midlands NHS Trust. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by University Hospitals of North Midlands NHS Trust · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 757 studies in Breast Neoplasms with a site in United Kingdom — 98 open to participants now, 195 under way, 67 of them phase 3. Breast Neoplasms · United Kingdom.

Planned enrollment
113th of 122
20 · median 221
Started
2026
with 12 others
Observational
123 of 757
30 open now
Primary completion
2027-12
later than 128 of 194 live
Registered
734th of 757
by date

Among the 757 studies in Breast Neoplasms with a site in United Kingdom, this one is the 113th largest by planned enrollment of the 122 observational ones that give a count, is one of 13 that started in 2026, is one of 123 observational ones, reaches primary completion later than 128 of the 194 other live ones, and was the 734th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

98 of the 757 studies in Breast Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

92 more — sign in →

All 98 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 757 studies in Breast Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this 6-month proof-of-concept study is to map out the chest wall perforators in relation to anatomical landmarks for partial breast reconstruction.

Read the detailed description

Breast conserving surgery is commonly performed in patients with breast cancer. It is important to fill the defect from a breast conserving procedure to achieve good cosmetic outcome. This defect can be filled either by using the adjacent breast tissue or by using perforator flaps; commonly taken from the area posterolateral to the breast or or below the inframammary crease. These perforator flaps can be based on thoracodorsal artery, lateral thoracic artery, lateral intercostal artery or the medial intercostal artery. The identification of these perforators using a hand-held doppler is an important but time-consuming intraoperative step. Surgeons often use the information derived from cadaveric studies when identifying these perforators as there is minimal information on the location of these perforators in relation to anatomical landmarks.

Patients with a BMI of \< 25 Kg/m2admitted for elective breast surgery or attending breast outpatients' clinic will be included in the study. Patients will be sent information about this study prior to admission or the clinic appointment with a copy of the consent form. Participants will have a 30-minute assessment using a hand held doppler and perforators will be mapped against soft tissue and bony landmarks. Data will be analysed to identify common anatomical locations for the different chest wall perforators.

03

Conditions studied

  • Breast Cancer Female

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The trial will be carried out at University Hospitals of North Midlands (UHNM). This will be a single centre study. Patients will be screened by the breast surgery Team for the eligibility criteria and recruited from the Breast Outpatients Clinic and marking of the perforators will be carried out on admission unit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing elective breast surgery
  • Age ≥ 18 years
  • Female
  • ≤ 30 kg/m2
  • Willing and able to give fully ,
  • Willing and able to comply with the study procedures

Exclusion criteria

Exclusion Criteria:

  • Pregnant patients
  • Previous bilateral Breast or axillary surgery
  • Undergoing bilateral oncoplastic procedure or requiring bilateral pre-operative marking
  • Undergoing breast surgery requiring pre-operative marking of some of the landmarks and has had contralateral breast or axillary surgery in the past
  • Surgery planned within 24 hours of screening for eligibility
  • Known history of allergy or contact dermatitis to ultrasound gels
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Location of vesselse

    The location of the AICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks

    Time frame: 6 months

  2. Location of vessels

    The location of the MICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks

    Time frame: 6 months

  3. Location of vessels

    The location of the LTAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks

    Time frame: 6 months

  4. Location of vessels

    The location of the LICAP vessels in vertical and horizontal axis using constant bony and soft tissue landmarks. This will be measured by the distance of the perforators from the anatomical landmarks

    Time frame: 6 months

Secondary outcomes

  1. Variability

    The degree of variability in location of the perforators.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 15 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 5, 2025
StartActual
Aug 4, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07006662
Lead sponsor
University Hospitals of North Midlands NHS Trust
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Aug 4, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Aviva Ogbolosingha
Contact
aviva.ogbolosingha@uhnm.nhs.uk
01782675380

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion